Nebenwirkungen · Fulvestrant Mylan
Fulvestrant Mylan 250 mg solution for injection in prefilled syringe · Abschnitt 4.8 · PDF-Seite 7
HOS-140286 · Präparat HOS-098490
Combination therapy with palbociclib The overall safety profile of fulvestrant when used in combination with palbociclib is based on data from 517 patients with HR-positive, HER2-negative advanced or metastatic breast cancer in the randomised PALOMA3 study (see section 5.1). The most common (≥20%) adverse reactions of any grade reported in patients receiving fulvestrant in combination with palbociclib were neutropenia, leukopenia, infections, fatigue, nausea, anaemia, stomatitis, diarrhoea, thrombocytopenia and vomiting. The most common (≥2%) Grade ≥3 adverse reactions were neutropenia, leukopenia, infections, anaemia, AST increased, thrombocytopenia, and fatigue.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-12T17:58:00Z · SHA-256 bb43ea0df59608c503a151e19f8c62d32b4dd74f427772bb1d98711eac8ff38f · Passage 879be322e8b2eb80943e1f31578b079b44aae509540e9d3b1663e601d1bc015a · Zeichen 6046–6718 im Abschnitt